X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express and secrete an active fragment of the full-length protein LEKTI. which is evaluated for the treatment of Netherton syndrome.
Lead Product(s): ATR-12
Therapeutic Area: Rare Diseases and Disorders Product Name: ATR12-351
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2024
Details:
The company intends to use the net proceeds for clinical trials and product development of ATR12-351 (ATR-12) for the treatment of Netherton Syndrome.
Lead Product(s): ATR-12
Therapeutic Area: Rare Diseases and Disorders Product Name: ATR12-351
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
The company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Lead Product(s): ATR-12
Therapeutic Area: Rare Diseases and Disorders Product Name: ATR-12
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 21, 2023
Details:
The Company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Lead Product(s): Strain of Staphylococcus Epidermidis
Therapeutic Area: Rare Diseases and Disorders Product Name: ATR-12
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2023
Details:
The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and consumer programs.
Lead Product(s): ATR-01
Therapeutic Area: Dermatology Product Name: ATR-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 15, 2020
Details:
The patent includes broad composition of matter claims that cover the Company’s engineered bacterial strain discovery platform, are central to its programs for treating skin diseases, and provide a significant barrier to entry for competitors.
Lead Product(s): Recombinant Staphylococcus epidermidis
Therapeutic Area: Dermatology Product Name: ATR-04
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
If ATR-12 is approved, Azitra would be eligible to receive a priority review voucher, which can be used for priority review of a drug marketing application for another product being developed by the company.
Lead Product(s): ATR-12
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
